Teeth, publisher of pharmaceutical product identification software, has just completed a funding round of 12 million euros with Naxicap Partners, Omnes Capital and CapHorn Invest. This operation allows the French start-up to cross the 20 million euros mark in funds raised over the last 18 months. Since its creation, the Massy-based company has raised nearly 25 million euros.
Founded in 2007 by Christophe Devins and David Carpentier, the French software publisher Adents designs solutions enabling individual product identification to be carried out. This approach is in the process of becoming essential in the pharmaceutical market. Indeed, several countries around the world have aligned themselves to require manufacturers of products in the sector to identify each box of prescription drugs with a unique code.
Ultimately, serialization aims to counter the expansion of counterfeit drug trafficking. The ax will fall in November 2017 in the United States while the European Union, and therefore France, will have until February 2019 to comply with the regulations of the health authorities.
The objectives of the Start-up
With this new investment, Adents plans to expand the development of its international network of “solution partners”, particularly in the United States, and to open up to new markets in the Middle East and Asia. To accelerate its commercial activity, the French start-up can now rely on a strategic partnership forged with the German industrial group Siemens. Since its launch, more than 2 billion unique codes have been generated and tracked around the world from software solutions developed by Adents.
Founders: Christophe Devins and David Carpentier
The head office : Massy, near Paris
Activity: Development of serialization and unit traceability software
Funding: 12 million euros in July 2016